Format

Send to

Choose Destination
See comment in PubMed Commons below
J Nucl Med. 2014 Jun;55(6):960-6. doi: 10.2967/jnumed.113.132928. Epub 2014 Apr 14.

Parametric Imaging and Test-Retest Variability of ¹¹C-(+)-PHNO Binding to D₂/D₃ Dopamine Receptors in Humans on the High-Resolution Research Tomograph PET Scanner.

Author information

1
PET Center, Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut jean-dominique.gallezot@yale.edu.
2
PET Center, Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut.
3
PET Center, Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut; and.
4
PET Center, Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut Department of Radiology and Psychiatry, New York University School of Medicine, New York, New York.
5
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut; and.

Abstract

(11)C-(+)-4-propyl-9-hydroxynaphthoxazine ((11)C-(+)-PHNO) is an agonist radioligand for imaging dopamine D2 and D3 receptors in the human brain with PET. In this study we evaluated the reproducibility of (11)C-(+)-PHNO binding parameters using a within-day design and assessed parametric imaging methods.

METHODS:

Repeated studies were performed in 8 subjects, with simultaneous measurement of the arterial input function and plasma free fraction. Two (11)C-(+)-PHNO scans for the same subject were separated by 5.4 ± 0.7 h. After compartment models were evaluated, (11)C-(+)-PHNO volumes of distribution (V(T)) and binding potentials relative to the concentration of tracer in plasma (BP(P)), nondisplaceable tracer in tissue (BP(ND)), and free tracer in tissue (BP(F)) were quantified using the multilinear analysis MA1 method, with the cerebellum as the reference region. Parametric images of BP(ND) were also computed using the simplified reference tissue model (SRTM) and SRTM2.

RESULTS:

The test-retest variability of (11)C-(+)-PHNO BP(ND) was 9% in D2-rich regions (caudate and putamen). Among D3-rich regions, variability was low in the pallidum (6%) but higher in substantia nigra (19%), thalamus (14%), and hypothalamus (21%). No significant mass carry-over effect was observed in D3-rich regions, although a trend in BP(ND) was present in the substantia nigra (-14% ± 15%). Because of the relatively fast kinetics, low-noise BP(ND) parametric images were obtained with both SRTM and SRTM2 without spatial smoothing.

CONCLUSION:

(11)C-(+)-PHNO can be used to compute low-noise parametric images in both D2- and D3-rich regions in humans.

KEYWORDS:

agonist; dopamine D2 receptor; dopamine D3 receptor; positron emission tomography; test–retest study

PMID:
24732151
PMCID:
PMC4201637
DOI:
10.2967/jnumed.113.132928
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center